• Lakewood-Amedex Biotherapeutics secured new gel-formulation patents for Bisphosphocin Nu-3 in Australia and New Zealand.
• New Zealand granted patent 759577 on Feb. 3, 2026; Australia granted patent 2024202211 on March 19, 2026.
• Patents cover Nu-3 topical gel formulation; Nu-3 is being advanced into a Phase 2 trial for mildly infected diabetic foot ulcers.
• Nu-3 gel formulation portfolio now totals 27 granted patents; overall IP estate totals 71 granted patents with 28 pending applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605270802PR_NEWS_USPR_____NY68330) on May 27, 2026, and is solely responsible for the information contained therein.